Surveillance of Adverse Events Following Varicella Vaccine Immunization in Zhejiang Province, China, from 2020 to 2022
<b>Background</b>: China has a high incidence rate of varicella yet a low coverage rate of the varicella vaccine (VarV), with safety concerns being a leading cause of the lack of vaccination willingness. This study aimed to describe VarV-related adverse events following immunization (AEF...
Saved in:
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2025-01-01
|
| Series: | Vaccines |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2076-393X/13/1/57 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832587401821683712 |
|---|---|
| author | Hui Liang Xiaohua Qi Yaping Chen Xuejiao Pan |
| author_facet | Hui Liang Xiaohua Qi Yaping Chen Xuejiao Pan |
| author_sort | Hui Liang |
| collection | DOAJ |
| description | <b>Background</b>: China has a high incidence rate of varicella yet a low coverage rate of the varicella vaccine (VarV), with safety concerns being a leading cause of the lack of vaccination willingness. This study aimed to describe VarV-related adverse events following immunization (AEFIs) and analyze their characteristics in Zhejiang, China, 2020–2022. <b>Methods</b>: VarV-related AEFIs in Zhejiang Province from 1 January 2020 to 31 December 2022 were collected through the Chinese National AEFI Information System (CNAEFIS) for a descriptive epidemiological analysis. <b>Results</b>: From 2020 to 2022, a total of 1477 VarV-related AEFI cases were reported (incidence rate: 34.79/100,000). The three most frequently reported clinical symptoms of common adverse reactions were fever, redness, and induration at the vaccination site. The distribution of VarV-related AEFIs varied significantly by age, dose, severity, and season. VarV-related AEFIs were more likely to be non-severe adverse events that occurred in the summer and winter seasons following the first dose of vaccine and among those under 3 years old. The top three regions with the highest incidence rates were Lishui City (59.53/100,000), Quzhou City (41.05/100,000), and Jinhua City (40.43/100,000). Most of the cases achieved full recovery without treatment (96.21%), and the rest were successfully treated without any sequelae. <b>Conclusions</b>: VarV demonstrates a safe profile in Zhejiang Province. Most VarV-related AEFIs are common reactions without requiring treatment, and the rates of rare and severe AEFIs remain low. Consistent monitoring, investigation, and diagnosis are needed to guide future VarV research and vaccination strategy adjustment. Our findings call for more policy changes, such as integrating VarV into China’s National Immunization Program and conducting more trials to evaluate the safety and effectiveness of VarV. |
| format | Article |
| id | doaj-art-fd7cb251edeb4b00a90c0ba7e30e720f |
| institution | Kabale University |
| issn | 2076-393X |
| language | English |
| publishDate | 2025-01-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Vaccines |
| spelling | doaj-art-fd7cb251edeb4b00a90c0ba7e30e720f2025-01-24T13:51:48ZengMDPI AGVaccines2076-393X2025-01-011315710.3390/vaccines13010057Surveillance of Adverse Events Following Varicella Vaccine Immunization in Zhejiang Province, China, from 2020 to 2022Hui Liang0Xiaohua Qi1Yaping Chen2Xuejiao Pan3Institute of Immunization and Prevention, Zhejiang Center for Disease Control and Prevention, Hangzhou 310051, ChinaInstitute of Immunization and Prevention, Zhejiang Center for Disease Control and Prevention, Hangzhou 310051, ChinaInstitute of Immunization and Prevention, Zhejiang Center for Disease Control and Prevention, Hangzhou 310051, ChinaInstitute of Immunization and Prevention, Zhejiang Center for Disease Control and Prevention, Hangzhou 310051, China<b>Background</b>: China has a high incidence rate of varicella yet a low coverage rate of the varicella vaccine (VarV), with safety concerns being a leading cause of the lack of vaccination willingness. This study aimed to describe VarV-related adverse events following immunization (AEFIs) and analyze their characteristics in Zhejiang, China, 2020–2022. <b>Methods</b>: VarV-related AEFIs in Zhejiang Province from 1 January 2020 to 31 December 2022 were collected through the Chinese National AEFI Information System (CNAEFIS) for a descriptive epidemiological analysis. <b>Results</b>: From 2020 to 2022, a total of 1477 VarV-related AEFI cases were reported (incidence rate: 34.79/100,000). The three most frequently reported clinical symptoms of common adverse reactions were fever, redness, and induration at the vaccination site. The distribution of VarV-related AEFIs varied significantly by age, dose, severity, and season. VarV-related AEFIs were more likely to be non-severe adverse events that occurred in the summer and winter seasons following the first dose of vaccine and among those under 3 years old. The top three regions with the highest incidence rates were Lishui City (59.53/100,000), Quzhou City (41.05/100,000), and Jinhua City (40.43/100,000). Most of the cases achieved full recovery without treatment (96.21%), and the rest were successfully treated without any sequelae. <b>Conclusions</b>: VarV demonstrates a safe profile in Zhejiang Province. Most VarV-related AEFIs are common reactions without requiring treatment, and the rates of rare and severe AEFIs remain low. Consistent monitoring, investigation, and diagnosis are needed to guide future VarV research and vaccination strategy adjustment. Our findings call for more policy changes, such as integrating VarV into China’s National Immunization Program and conducting more trials to evaluate the safety and effectiveness of VarV.https://www.mdpi.com/2076-393X/13/1/57varicella vaccineadverse eventsAEFIsurveillanceChina |
| spellingShingle | Hui Liang Xiaohua Qi Yaping Chen Xuejiao Pan Surveillance of Adverse Events Following Varicella Vaccine Immunization in Zhejiang Province, China, from 2020 to 2022 Vaccines varicella vaccine adverse events AEFI surveillance China |
| title | Surveillance of Adverse Events Following Varicella Vaccine Immunization in Zhejiang Province, China, from 2020 to 2022 |
| title_full | Surveillance of Adverse Events Following Varicella Vaccine Immunization in Zhejiang Province, China, from 2020 to 2022 |
| title_fullStr | Surveillance of Adverse Events Following Varicella Vaccine Immunization in Zhejiang Province, China, from 2020 to 2022 |
| title_full_unstemmed | Surveillance of Adverse Events Following Varicella Vaccine Immunization in Zhejiang Province, China, from 2020 to 2022 |
| title_short | Surveillance of Adverse Events Following Varicella Vaccine Immunization in Zhejiang Province, China, from 2020 to 2022 |
| title_sort | surveillance of adverse events following varicella vaccine immunization in zhejiang province china from 2020 to 2022 |
| topic | varicella vaccine adverse events AEFI surveillance China |
| url | https://www.mdpi.com/2076-393X/13/1/57 |
| work_keys_str_mv | AT huiliang surveillanceofadverseeventsfollowingvaricellavaccineimmunizationinzhejiangprovincechinafrom2020to2022 AT xiaohuaqi surveillanceofadverseeventsfollowingvaricellavaccineimmunizationinzhejiangprovincechinafrom2020to2022 AT yapingchen surveillanceofadverseeventsfollowingvaricellavaccineimmunizationinzhejiangprovincechinafrom2020to2022 AT xuejiaopan surveillanceofadverseeventsfollowingvaricellavaccineimmunizationinzhejiangprovincechinafrom2020to2022 |